Presenilin 2 (PSEN2) constitutes the essential catalytic subunit of the γ-secretase intramembrane protease complex. Mutations in the PSEN2 gene are directly implicated in early-onset familial Alzheimer's disease (FAD-type 4). Unlike its homolog PSEN1, PSEN2 exhibits restricted tissue distribution and distinct subcellular localization, making it a highly compelling target for selective γ-secretase modulators (GSMs) aimed at reducing amyloid-β (Aβ42) production while sparing Notch signaling.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSEN2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSEN2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for antibody screening and binding assays. |
View PSEN2 Products |
| Gene Delivery | PSEN2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Crucial for preserving 9-transmembrane native conformation. |
View PSEN2 Products |
| Benchmark Ab | Anti-PSEN2 Antibody Recombinant positive control for expression validation and functional blocking assays. |
View PSEN2 Products |
| Validator | PSEN2 siRNA Set For knockdown verification in functional γ-secretase cleavage assays. |
View PSEN2 Products |
| Related Target A | PSEN1 Highly homologous γ-secretase subunit. Essential for counter-screening to ensure PSEN2-selective drug profiles. |
View PSEN1 Products |
| Related Target B | APP Amyloid Precursor Protein. The primary substrate cleaved by the PSEN2-containing γ-secretase complex to yield pathogenic Aβ peptides. |
View APP Products |
| Related Target C | NCSTN Nicastrin. A key structural component of the γ-secretase complex required for substrate recognition. |
View NCSTN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Transmembrane Conformation Loss | Lentivirus-based full-length expression ensures native 9-TMD folding in stable host cell lines. |
| PSEN1 vs. PSEN2 Off-target Screening | Matched ortholog and homolog panels (PSEN1/PSEN2) strictly verified by sequence and mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies and custom positive controls included in the catalog. |
| False Positives in Knockdown Studies | Sequence-validated siRNA pools included to confirm target-specific phenotypic rescue. |
Live PSEN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the γ-secretase complex is undergoing a significant renaissance. Early clinical failures of non-selective γ-secretase inhibitors (GSIs) due to severe gastrointestinal toxicity—driven by the inhibition of Notch cleavage—have redirected R&D toward selective Gamma-Secretase Modulators (GSMs). Today, the focus is heavily shifted toward PSEN2-specific modulation. Because PSEN2-containing complexes are localized primarily to late endosomes and lysosomes, targeting PSEN2 offers a highly localized therapeutic window, minimizing systemic Notch toxicity while effectively reducing the intracellular pool of toxic Aβ oligomers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GSMs) | Roche, Eisai, Eli Lilly | Alzheimer's Disease, Familial AD | Selectivity Assay (Need mutant vs. WT proteins to screen for FAD-specific modulators) |
| Gene Therapy / RNAi | Alnylam, Ionis Pharmaceuticals | Neurodegenerative Disorders | Target Knockdown Verification (Need high-specificity PSEN2 siRNA and qPCR primers) |
| Monoclonal Antibodies | Academic Consortia, Biotechs | Oncology (Notch-driven cancers) | Conformational Binding (Need cell-based assays via Lentivirus-transduced stable lines) |